Painmanagementisanever-evolvingfield,withnew
treatmentsandtechnologiesemergingallthetime. Asthehealthcareindustryshiftstowardsamore patient-centeredapproach,thereisagrowingneedforpain managementsolutionsthataresafe,effectiveandtailoredto individualpatientneeds.
Oneoftheemergingtrendsinpainmanagementistheuse ofnon-pharmacologicalinterventions.Withthegrowing concernoveropioidaddictionandabuse,nonpharmacologicalinterventionslikecognitive-behavioral therapy,acupunctureandphysicaltherapyarebecoming increasinglypopular Thesetreatmentsareeffectivein managingpainandhavefewersideeffectsthantraditional painmedications.
Anotherpromisingtrendistheuseofdigitalhealthtoolsto managepain.Theuseofmobileappsandwearablestotrack painsymptomsandmedicationusageisontherise.These toolsprovidepatientswithreal-timedataabouttheirpain levelsandcanhelphealthcareprovidersmakemore informeddecisionsabouttreatmentoptions.
Personalizedmedicineisalsoplayinganimportantrolein thefutureofpainmanagement.Withadvancementsin genomicsandmolecularbiology,healthcareproviderscan identifygeneticvariationsthatinfluenceapatient'sresponse
topainmedications.Thisinformationcanbeusedto developpersonalizedtreatmentplansthataremoreeffective andhavefewersideeffects.
Innovativemedicaldevicesandtherapiesarealso transformingpainmanagement.Deviceslikespinalcord stimulatorsandperipheralnervestimulatorscanprovide reliefforchronicpainsufferers.Emergingtherapieslike stemcelltreatmentsandregenerativemedicineshowgreat promiseinrepairingdamagedtissueandreducing inflammation.
Finally,thereisagrowingrecognitionoftheimportanceof interdisciplinarycareinpainmanagement.Ateam-based approachthatincludeshealthcareprovidersfromdifferent specialties,suchaspainmedicine,physicaltherapyand psychology,canprovidepatientswithcomprehensivecare thataddressesallaspectsoftheirpain.
InInsightsCare'slatesteditionMostPromisingPain ManagementSolutionProviders2023,webringtoyoua comprehensivelistofcompaniesthatareleadingthecharge inprovidinginnovativesolutionstotacklepain management,acriticalissuethataffectsmillionsofpeople worldwide.
Hope you have an interesting read!
-PoojaShah
Senior Editor
Anish Miller
Editor-in-Chief
Merry D'souza
Managing Editor Pooja Shah
Visualiser David King Art & Design Head
Mrunalinee Deshmukh
Business Development Manager
Amy Jones
Marketing Manager John Smith
Co-designer Paul Belin
Assisting Editors Saloni, Shreyasi
Art & Picture Editor Sonia Raizada
Business Development Executives
Sarah Wilson, John Smith, Alex Vincent
Technical Head
Jacob Smile
Digital Marketing Manager
Alina Sege
Assistant Technical Head Prachi Mokashi
Assistant Digital Marketing Manager
Renuka Kulkarni
Research Analyst
Eric Smith
Sales Executives
Kelli, Bill, Anna
Technical Consultants
David, Robert
SME-SMO Executives
Gemson
Circulation Manager
Tanaji Fartade
sales@insightscare.com Contact Us:
February, 2023
Success Media Tech LLC 555 Metro Place North, Suite 100, Dublin, OH 43017, United States Phone - 302-319-9947
Email: info@insightscare.com
For Subscription: www.insightscare.com
Insights Success Media and Technology Pvt. Ltd. Survey No133/134, Brand Square, Office No. 512, Kunjir Chowk, Pimple Saudagar, Pune, Maharashtra 411027
Phone - India: 7410033802, 74100058552
Email: info@insightscare.com
For Subscription: www.insightscare.com
Artelo Biosciences, Inc. Artelobio.com
Bridges Paliative Care Bridgespalliativecare.com
DORN Dorncompanies.com
Gregory D. Gorgas CEO & President
Artelo Biosciences, Inc. is a clinical stage company focused on modifying lipid-signaling pathways to improve treatments for people living with cancer
Erik Soiferman Owner
Kevin Lombardo President CEO
Bridges Paliative Care’s goal is to help you achieve the best possible outcome and overall quality of life throughout your illness.
DORN is a disruptive innovator and the country’s leading wellness-based pain management and injury prevention company, committed to reducing costs of healthcare, workers’ compensation and lost productivity
KIPUWEX OY LTD Kipuwex.com
Marko Höynälä CEO & Founder
KIPUWEX OY LTD is a small wireless IoT device that continuously measures different physiological parameters from the patient digitally, converting them with an algorithm into pain data and provides efficiently reliable measurements for healthcare professionals and home users.
Nen Nen.health
Plymouth Bay Orthopedic Associates, Inc. Pborthocom
Rescape Rescape.health
Soovu Labs, Inc Soovu.com
Francesca Wuttke / Xenia Riasol Founder & CEO / COO
Nen provides evidence based health designed for children’s minds to improve their lives.
Alan Doucet Executive Director Plymouth Bay Orthopedic Associates, Inc. goal is to help patients live a more active and rewarding life.
Matt Wordley CEO
Allan Stephan Co-founder and CEO
Rescape California is a non-profit organization that educates about and advocates for a whole-systems approach to landscaping that works in harmony with the natural world and addresses the changing environment
Soovu Labs, Inc helps individuals overcome pain and get back to their lives and work
Acrossthehealthcarecommunity,aserious
challengewhiledeliveringcareisassistingpatients withbothacuteandchronicpainmanagement. Particularlysoforpeoplelivingwithcancer
Theinitialstageoftreatinganydiseaseorailmentis diagnosingthecauseandtreatingitwithappropriate interventions,includingdrugsorvariedtherapeutic approachesasrequired.However,astandarddiagnosistreatment-healingparadigmdoesn’talwaysworkwellfora personlivingwithcancer.
Throughthecancertreatmentjourney,apersondiagnosed withcancermayencounterconsiderableperipheralpain (neuropathy),boneinflammation,gastrointestinalinfection, lowmusculoskeletalfunctionality,orothercomplications.A 2020publichealthresearchindicatesthat around 20% to 50% of cancer survivors experience pain. Yet, 30% of those who do not receive relief from their pain experience a negative impact on their quality of life. As cancer advances, pain can intensify by up to 80%, severely impacting a person’s quality of life. Thesestatisticsmotivatethe researchcommunitytodiscovernewandrobustsolutions.
Onepotentialalternativeemergingfromclinicalresearchon cancerpainhasspotlightedtheroleofthebody’sown EndocannabinoidSystem(ECS).Thiscell-signaling networkisoneofthelargestinthebodyandisassociated withregulatingpainsensation.
AtArteloBiosciences—a clinical-stage company using cutting-edge science to improve patient care,drug developmentbasedupontargetingtheECSisshowing
drug candidate, ART26.12 has the poten al to stand out in the market due to its poten al therapeu c value in preven ng and trea ng chemotherapy-induced peripheral neuropathy (CIPN), a common and o en painfully debilita ng complica on of cancer therapies.
Artelo’sUsing Cu ng-Edge Science with Lipid-Signaling Modula on to Improve Trea ng People with Cancer
promise.Thecompanyappliesleading-edgescientific, regulatoryandcommercialdisciplinestodevelop innovativetherapies,withaparticularfocusontheneedsof thecancerpatient.RealizingthemeritoftargetingtheECS, Arteloisonamissiontoalterthecourseoftreatmentfor thosediagnosedwithcancerandotherseriousconditions.
SpearheadingArtelowithinnovation,convictionand leadershipisthecompany’sPresidentandChiefExecutive Officer—GregoryD.Gorgas.Committedtoimprovingthe livesofthemillionsofpatientsworldwidewithcancer diagnosis,herecruitedateamoflike-mindedresearchers, clinicalprofessionalsandbusinessexecutivesinSanDiego andabroadtocreateArtelo.
AcknowledgingsuchprogressatArtelo,wecrossedpaths withGregoryGorgastolearnmoreaboutthecompanyand itsmissiontomeaningfullyimpactcancercare.
Let’s dive in to know more!
ArteloBiosciences—AtaGlance!
Arteloisastoryofempathy,innovationandscientific revolution.Beingenrichedwiththevisionandoperational experienceofitsCEO—GregoryGorgas,thecompanyaims totransformthecareofalargenumberofpeoplesuffering throughmultiplediseasesandconditions,includingcancer, pain,anorexia,anxiety,neuropathy,andinflammationwith thehelpofitsnovelproductcandidatesindevelopment designatedasART27.13,ART26.12,ART12.11.Awareof thetremendouspromiseoftargetingtheECSwithlipidmodifyingdrugstotreatcancer,painandcentralnervous system(CNS)-relatedconditions,Arteloinitiateditsquest forinnovativeresearchearlyin2017.Bytheendofthat year,thecompanyhadacquiredrightstomultiple technologiesandfiledapatentonitsowninvention.Insum, Artelo’sportfoliorepresentsthebroadestspectruminthe pharmaceuticalindustryofmethodstargetingtheECSfor theimprovementofhealth.
Inearly2023,Arteloexpectstostartenrollingpatientsin thePhase2stageoftheCancerAppetiteRecoveryStudy
(CAReS)withitsleadclinicalprogram,ART27.13.Cancer anorexia(lossofappetiteoraversiontofood)affectsover 60%ofpeoplewithacancerdiagnosisandisaleading causeofdeathforcancerpatients.ART27.13wasdesigned toarresttheanorexiaandresultingweightlossexperienced bythemajorityofcancerpatients.Liketheotherprograms atArtelo,ART27.13targetsthereceptorsoftheECS.It leveragesaknowneffectonhungerwithouttheundesired CNSeffectsofcannabis.Andthecompanyiswell-funded tocompletetheCAReStrialasitslastreportedcashwas nearly$20million.
Anothercomplicationofcancerispainsecondarytothe toxiceffectsofcertaincancerchemotherapies.Akey initiativeofArteloistobringitsseconddrugcandidateinto theclinicwithinthenext18months.Inmultiplepreclinical animalstudies,ART26.12hasshownremarkablepromisein treatingpainfulneuropathiesassociatedwithchemotherapy Artelo’sresearchersshowedthatART26.12wasabletonot onlysuccessfullytreatthepain,butalsopreventthe neuropathicpainfromevenstarting.Currently,thereareno FDA-approvedtreatmentsforchemotherapy-induced peripheralneuropathy(CIPN).Arteloisonamissionto changethat.
ART26.12isanewchemicalentity.BecauseART26.12is attheforefrontofArtelo’sinnovation,weaskedMr.Gorgas toelaborateonthescienceandstrategywiththisnovel compound.HeexplainedthatART26.12isaselectivefatty acidbindingprotein5(FABP5)inhibitor.Itinhibitsa pathwaythatcanraiseendogenouslevelsof endocannabinoids,thebody’sself-madecannabinoids. ART26.12hasthepotentialtostandoutasatreatmentdue toitstherapeuticvalueinpreventingandtreatingCIPN,a commonandoftenpainfullydebilitatingcomplicationof cancertherapiesthatoftenresultsinareductionor interruptionofcancertreatment.CIPNisfrequentlyso painfulthatpatientscannotprogressontheiranti-cancer therapy
Inpreclinicalmodels,inhibitionofFABP5usingART26.12 hasshownactivityinanalgesia,reversingtheeffectsof CIPN,aconditionforwhichtherearecurrentlyno approvedtreatments.Currentpainmanagementmedications typicallyhavesignificantsideeffectsand/oraddictive properties.Todate,FABP5inhibitionhasshownlittleto noneoftheseeffectswhileexhibitinggoodanalgesic properties.
Inadditiontopain,inhibitingFABP5maybeusefulinother areasofunmetneed.Ofrecentnote,landmarkresearchin
anxietywithanotheroneofArtelo’sFABP5inhibitorswas selectedasoneofthetop50(outof12,000researchstudies submitted)attheSocietyofNeuroscienceannualmeeting inNovember2022.Thepreclinicalresultsindicatedthata novelFABP5inhibitorfromArtelo’sextensivelibraryof FABPinhibitorssignificantlyreducedanxietybehaviors withouttheabusepotentialorcognitionbluntingofother treatmentsforanxietydisorders.There,itwasconcluded thatmodulationoftheFABP5systemmightserveasa promisingtargetforthedevelopmentofnovelanxiolytics.
Artelo’sfull-spectrumapproachtomodulatingtheECS withlipid-modifyingapproachesinclude:.
Ÿ ART27.13,acannabinoid(CB andCB)receptor 1 2 agonist,beinginvestigatedintheCAReStrial,currently enrollingpatientswithcanceranorexia.
Ÿ ART26.12,afattyacidbindingprotein5inhibitor,with regulatory-enablingstudieswellunderwayaimingto havetheprogramintheclinicforchemotherapyinduced peripheralneuropathywithin18months.Afirstfora FABP5inhibitor
Ÿ ART12.11,apatentedcocrystalcompositionof cannabidiol(CBD),inpreclinicaldevelopmentfor anxiety-relateddisordersincludingpost-traumatic syndromedisorder(PTSD),aswellasotherpotential indications.
If approved by the FDA, ART27.13 in cancer anorexia and ART26.12 in chemotherapyinduced peripheral neuropathy would be first-in-class treatments for people that have no currently approved treatment op ons.
IfapprovedbytheFDA,ART27.13incanceranorexiaand ART26.12inchemotherapy-inducedperipheralneuropathy wouldbefirst-in-classtreatmentsforpeoplethathaveno currentlyapprovedtreatmentoptions.Arteloalsobelieves itsCBDcocrystalhasthepotentialtobeabest-in-class drug.
WhileseveralofArtelo’sprogramsmayultimatelybe usefulasanti-canceragentsdirectly,Mr.Gorgassaysthe missionofArtelotodayistotreatthewholepersonwith cancer Whiletherehavebeenmanyadvancementsinthe treatmentoftumorsoverthepasttwodecades,cancerpain andcanceranorexiaarestillwithoutFDA-approved treatments.Mr.Gorgaslamentedthattreatmentofcancer anorexiahasnotadvancedsincehestartedhiscareerinthe pharmaceuticalindustrynearly40yearsago,andtheteam atArteloaimstochangethat.Usingamechanism-based approachmodulatingtheECSholdstherapeuticpromise thatmayhaveeludedresearchtodate.
Artelo’spriortiesfor2023are1.)therapidaccrualinthe CAReSPhase2withanexpansionofclinicalsitesin UnitedKingdomandEurope,2.)gainingalignmentwith theFDAonthepathwayandresearchtobringART26.12
management medica ons typically have significant side effects and/or addic ve proper es. But to-date, Artelo’s FABP inhibi on has shown li le-to-none of these effects while exhibi ng good analgesic proper es.
intotheclinicforCIPN(afirstforaFABP5inhibitor),and 3.)advanceandexpandtheunderstaningofdifferentiating propertiesofitspatentedCBDcocrystal.
Mr.Gorgasbringsalmostfourdecadesexperiencetohis roleinleadingArtelo.BeforefoundingArtelo,heservedas SeniorVicePresident,CommercialandCorporateOfficerat MastTherapeutics,apublicly-heldbiotechnologycompany. There,hehadcommercialleadershipaccountabilityand businessdevelopmentresponsibilitiesforthehematology, oncologyandcardiovascularfranchises.Priortothat,he workedatBiogen,apublicly-heldbiotechnologycompany, asSeniorDirector,GlobalMarketing,withresponsibility forthestrategicvisionandoperationalcommercialization ofthecompany’sworldwidecancerbusiness.
Furtheringhiscommitmenttobringhealingtopeopleliving withcancerthroughinnovativetherapeutics,Mr.Gorgas becameconvincedthattargetingthebody’s endocannabinoidsystemwithlipid-signalingdrugscould leadtonewsolutionstooldproblems.ThisledMr.Gorgas toestablishArtleoBiosciences.ModulatingtheECSwith federally-compliantcannabinoid-baseddrugresearchhas someaddedcomplexityandchallenges,butthe transformativepotentialoftheprogramsatArtelomakesit worththeeffort.AndArtelohasacompetitiveadvantageof havingsuccessfullynavigatedcomplexregulationsto advanceitsprogramsacrosstheglobe.
Mr.Gorgasenvisionsbenefitingmillionsofpatients worldwidethroughtheproductdevelopmentatArtelo Biosciences.Thecompanyseekstoattainthisvision throughtheapplicationofinnovative,next-generation sciencetoreal-worldchallengesforpeoplelivingwith cancer.Currently,alongsidethebusinesspotential,Mr. GorgasandtheteamatArteloderivetheirmotivationto solvepharmaceuticalchallengesthathaveeludedthe industryfordecades.
Yearsago,Mr.GorgasreadPeterMedawar’s“Advicetoa YoungScientist,”whowrote,“In choosing topics for research...to enlist in, a young scientist must beware of following fashion.”Mr.Gorgasfoundittobeanessential suggestion.
FollowingfashioninscienceoronWallStreetoftenleads todeadends.“WhenwestartedArteloin2017,federally-
compliantresearchintotheendocannabinoidsystemwas verynewandfewdaredtopursuethepath,butthatdidn’t dissuadeus.Wewereconvincedthatlipid-modulatingdrugs wouldultimatelyprovetheirvalueintreatingserious medicalconditionslikecancerpainandanorexia,”saysMr. Gorgas.“Decadesofcommitmentandsmartscience pursuedbypioneerresearchersintheECSlikeArtelo’s ChiefScientificOfficer,AndyYates,Ph.D.,andProfessor SaoirseO’Sullivan,Ph.D.,nowArtelo’sVicePresidentof TranslationalResearcharebeginningtopaydividends.We areexcitedtobealeadingcompanywiththisinnovation, andthroughoureffortswehopepeoplewithcancerwill livebetterinthedecadestocomethanindecadespast.”
ArteloBiosciencesistradedontheNasdaqCapitalMarkets exchange(Nasdaq:ARTL)andhasanalystcoveragewith LadenburgThalmann&Co.Inc.,H.C.Wainwright&Co., andMaximGroup.
Patientswhofacecommunicationadversities,suchas youngchildren,peoplewithmentalillnesses,and criticallyillpatients,havedifficultybeingassessed forpain.Prematureinfantswhosecentralnervoussystems havenotyetformedandmayexperiencedisastrouseffects requirespecificattentionwhenitcomestopaintreatment.
MarkoHöynäläistheCEOandFounderofKipuwex,a companythatdevelopsasmallwirelessIoTdevicethat continuouslyrecordsapatient'sphysiologicalparameters digitally,convertsthoseparametersintopaindatausingan algorithm,andprovidesaccuratemeasurementsforboth healthcareprofessionalsandat-homeusers.
Markoisagloballywell-knowninventorfromOulu, Finland,withglobalexperienceinmultipletechnology fronts,includingtheIoT(InternetofThings),IoMT (InternetofMedicalThings),AI(ArtificialIntelligence), RemotePatientMonitoring(RPM),andtelehealth industries.
Here are the interview specifics that shed light on the pressing need to address chronic pain assessment and how Marko Höynälä is overcoming this obstacle with Kipuwex.
KindlybriefusaboutKipuwexanditsinceptionstory.
Chronicpainisadeeplypersonalissuetome,asmyfather sufferedfromcancer.Isawhowdestructivechronicpain canbe.Hecouldn’thandlethepainandcommitted suicide.Chronicpainisoneofthelargest medicalburdensworldwide;wecan’teven measureitconsistently,sohowcanwetreat itproperly?
Painisoftenunderdiagnosedor overtreated,bothofwhichhave long-termimpactsonthelivesofthoseit
affects.Itwastheyear2015whenIcameacrossthelocal NorthernOstrobothniaHospitalDistrict’sinnovation competition,inwhichfourmajorglobalproblemswere facedbyhealthcareprofessionals.
Oneofthedifficultieswasobjectivelymeasuringthe children'spain.Iwonthecompetition,andthatwasthestart oftheKipuwexcompany.Itwashighlyimportantthat winningthehospitaldistrict’sinnovationcompetitionmeant gettingtoworkcloselywithhealthcareprofessionals.
Today,wehaveextendedourcollaborationswithleading medicalinstitutionsandhospitalswithinEuropeandAsia. Atfirst,westartedtodevelopanautomaticandobjective medicaldeviceforpainmeasurement,butduringthe journey,wechangedourstrategy
Kipuwexdevicewillbelaunchedinthehealthcaremarket asacomprehensiveremotemonitoringdevice.Inthe secondphase,wewillintegrateapainmeasurementfeature.
WhatarethecorevaluesofKipuwex,andhowareyou drivingKipuwextoachieveitsmissionandvision statement?
Ihaveover20yearsofexperienceinsoftware development,soithasbeenverylogicalthatourcore competenciesaresoftware,developingcloudservices, algorithms,applications,andalltheotherIoT(Internetof Things)andIoMT(InternetofMedicalThings) technologies.
WithKipuwex,wewanttotacklethreemajorhealthcare problems.risingcostsofhealthcare,e.g.,intheUSA,20% ofGDPgoestohealthcare.There'salackofaccessto affordablehealthcare;atleasthalfoftheworld’s8billion peoplestilldonothaveaccesstoessentialhealthservices. Chronicpainisamajorglobalissue,affecting20%of
adultsworldwideandcosting$560-635billioninthe UnitedStatesaloneeachyear.
"Kipuwex’s mission is to combat healthcare inequality and help millions of people."
"Kipuwex’s vision is to become a world-leading company in the pain management domain."
Enlightenourreadersaboutthekeyproductsand offeringsofKipuwexandhighlightanyservicethatisits USP.
Kipuwexisasmall,wirelessIoMTdevicethatmeasures12 differentphysiologicalparameters,includingpain.The deviceisattachedtothepatient’schestwithadisposable ECGsticker Wemeasuremorephysiologicalparameters thananyothersimilardeviceonthemarket.Wehave developedKipuwexsothatitisaffordablefordeveloping countriesaswell.
Currently,wearedevelopingforhomeusersthefirst completehealthreportintheworld.It'saconsumer-centric digitalhealthecosystemforremotepatientmonitoringin cooperationwithauniqueglobalpartnership.Also,there arewell-beingalgorithmsforpreventivecareand personalizedheartandemotionalwell-beingmonitoring.
Inyouropinion,whatarethecurrentchallengesinthe painmanagementindustry?Howareyouinfusingyour leadershipskillsandexpertiseovertheyearstocreatea flourishingindustrywithopportunitiesandgrowth?
Themedicaldevicebusinessisverychallenging.It’savery longprocesstodevelopanewmedicaldeviceandtolaunch it.Theroadtoasuccessfullaunchcanbefilledwithproduct developmentrisks.Ofcourse,itinvolvesnumerouslegal andeconomicconsiderations,soweneedtothinkand
Kipuwex’s advantage and competitiveness are based on the fact that the company has integrated so many sensors into such a small IoMT device.
apply.Companiesmustcomplywithregulations,whichcan betime-andmoney-consuming.
Thebiggestchallengeishowtomakefundinglastthrough productdevelopmentandtogetsufficientfundingto finalizetheproductdevelopment.Theglobalpandemicwas ahugechallengeandpostponedclinicaltrials.Product testingshouldbeginearlyinthedevelopmentprocessand continuethroughout.ThewarinUkrainehascausedalack ofcomponents.
Thepresentresearchisservingasthebaselineforbetter futurestrategiestoimproveglobalhealthinitiatives,asour ecosystemisveryscalableandcanbeintegratedaswell. Wearegettingcontinuousquestions,isitpossibleforthird partiestointegrateourplatformintheirownusecases? Opportunitiesarequiteendlesswhenthinkingofgrowth potential.
Whatarethelatesttechnologicaladvancementsadopted byKipuwextodeliverthebestpainmanagement servicesintheindustry?Howisitimpactingthe demographicconcerned?
Kipuwexproductisprotectedbypatentsandknow-how. Ouradvantageandcompetitivenessarebasedonthefact thatwehaveintegratedsomanysensorsintosuchasmall IoMTdevice.Forthepainmeasurementfeature,weare grantedtwopatents,whichareessentialandextremely importanttostimulatetheinnovation,developmentand commercializationofKipuwex.
Asanexperiencedleader,whatwouldbeyouradvicefor aspiringentrepreneursandenthusiastswhowishto ventureintotheMedTechsector?
Beinganentrepreneurisdifficult,especiallyinthe MedTechindustry,whichisdifficultinmanyways.Italso
needsyearsofhardworktogotomarket.Youmusthavea strongvision,missionandproblem-solvingabilitiesthatare morethanjustbusinesstoyou.
WhatarethefuturegoalsofKipuwex,andHowdoyou envisionscalingupitsoperationsandreachin2023and beyond?
Kipuwex'smissionistoprovideremotemonitoringdevices throughouttheworld.Our vision is to become a worldleading company in the pain management domain.
“Billions of people still do not have access to essential health services, and at the same time, health care costs are unsustainable across the world. Next generation sensor technologies, in combination with smart algorithms, bring unlimited opportunities to ensure accessible and affordable healthcare solutions. Kipuwex remote monitoring device is well positioned to play an important role in revolutionizing the integration of quality healthcare outside hospitals.”
Ÿ Prof.Dr.NiclasAdler, CEO and Founder of Adler Industries. CEO and Founder of Synthesis Group, iHealth Solutions, and iPower Group. Stockholm, Sweden
“Kipuwex is one of the state-of-the-art devices for pain management, which is the need of the hour in this era of digitalization and can revolutionize pain management in certain sectors of the population. It also has the promise of being utilized as a unique remote vital parameter monitoring device such as in emergency kits, and such devices have now become a necessity.”
Ÿ Prof.Dr.MCh.BJRajes, Consultant Neurosurgeon at Yashoda Hospitals, Hyderabad, Telangana, India
Sincepainisasubjectiveexperience,eachperson
experiencesitdifferently.Physicalorpsychological paincanaffectaperson'smentalandemotionalwellbeing.Tormenttheboardincludesvariousstrategiesand techniquestoassistpeoplewithdealingwiththeir aggravation.
Psychologicalexplanationsforpainmanagementcanalso bebeneficial,inadditiontophysicaltreatmentsliketherapy andmedication.
Let's examine the psychological basis for pain management and its benefits!
Psychologicalpainmanagemententailstheapplicationofa varietyofstrategiestoassistindividualsincopingwith pain.Accordingtothepsychologicalexplanationofpain management,painisbothaphysicalandapsychological experience.Thisindicatesthataperson'sthoughts,feelings andactionscanimpactpain.
Accordingtothepsychologicalexplanationofpain management,thesepsychologicalfactorscanbeaddressed tomanagepain.Forinstance,aperson'sperceptionofpain canbeinfluencedbytheirbeliefs.
Aperson'spainmaybecomemoresevereiftheybelieveit isintolerableandunmanageable.However,peoplemayfeel moreincontroloftheirpainiftheythinkitcanbe managed.
Fearofpainisnormalbecauseitisanaturallearningtool andahorriblefeeling.Patientswhoexperiencepersistent paintendtodevelopafearofpainand,asaresult,stop doingactivitiesthatmakethemfeelpain,suchasmoving theirbodies,whichistypicalofosteoarthritis.
Througheducation,rethinkingpain,cognitivebehavioral therapy(CBT),andtheothermethodsonthispage,the cycleofchronicpainanddisabilitycanbebroken.Thisfear ofpaincanbecomeacyclethatneverends.
Oneapproachforpsychologicalpainmanagementis cognitivebehavioraltherapy(CBT).Thegoalofcognitive behavioraltherapyistoassistpeopleinrecognizingand alteringnegativethoughtsandactionsthatcausepain.CBT, forinstance,canhelppeoplechallengethebeliefthatthey areweakordamagedduetopainanddevelopmorepositive andrealisticviews.
Careisonemoremethodutilizedinthementaltormentof theboard.Beingawareofthepresentmomentand acceptingitwithoutjudgingitismindfulness.Stressand anxietycanbereducedthroughmindfulness,whichcan assistindividualsinpainmanagement.Stressand nervousnesscanexacerbatetheaggravation,sodiminishing thesefeelingscanassistwithoverseeingtorment.
Massagetreatment,likeunwinding,iscommonlyutilizedas anassistanttoconventionaltreatmentmodalities.Itis generallyusedclosebyandcontrastedwithunwindingand othermentalmedicines,sorememberingwasconsidered advantageous.
Sinceitsinceptioninthe2ndcenturyBC,massagetherapy hasdevelopednumeroustechniquesandsubfields, includingSwedishmassage,Shiatsu,Rolfing,reflexology, andcraniosacraltherapy.
Inoneofthestudies,massagewasmoreeffectivethana placebotreatment.Intheremainingsevenstudies,therewas nosignificantdifferencebetweenexercisesandcorsets,and themassagewassuperiortorelaxation,acupunctureand education.
Relaxationcantakeavarietyofforms,includingspiritual ornon-spiritualmeditation,progressiverelaxationor muscularcontractionandrelaxation,andevenimagery.Itis generallyusedinconjunctionwithothertreatment modalities.
Typically,relaxationisconsideredan"Alternative" treatmentthatmustbeusedinconjunctionwith conventionalmedicalcareratherthanonitsown.This couldbebecausethetreatment'stheoreticalfoundations
haven'tbeenprovenorthereisn'tenoughhigh-quality evidencetosupportit.
Restoringnormalequilibriumwithinthebody'ssystemsis onewaythatrelaxationtherapymaybeeffective.Thiscan beaccomplishedbyreducingtheeffectsofstressonthe body Thebody'smostfundamentalresponsetostressisa "fightorflight"responsethattriggersseveralbiochemical changes.
Thepsychologicalexplanationforpainmanagementhas numerousadvantagesoverspinalmanipulationand transcutaneouselectricalnervestimulationintermsof effectiveness.
First,itcangivepeopleasenseofcontrolovertheirpain. Peoplemayfeelmoreempoweredtomanagetheirpain whentheyrealizetheirthoughtsandactionscanaffectit. Self-confidenceandself-esteemmayriseasaresult.
Second,thesemethodsmaylessentherequirementfor medication.Medicationcanpotentiallyalleviatepain,butit canalsohaveadverseeffectsandbecomeaddictive. Psychologicaltechniquescanbeusedtomanagepain independentlyorwithmedication.
Thirdly,psychologicalpainmanagementhasthepotential toenhanceaperson'squalityoflife.Tormentcan essentiallyaffectanindividual'spsychologicaland profoundprosperity.Peoplecanimprovetheirmood, reducestressandanxiety,andparticipateinmoresocial activitiesbycontrollingpain.
In sum-up,
Thepsychologicalexplanationofpainmanagement suggeststhatpainisapsychologicalandaphysical experience.Peoplecanbettermanagetheirpainby addressingthepsychologicalfactorsthatcauseit.
Psychologicalmethodsformanagingpain,suchas cognitivebehavioraltherapy(CBT)andmindfulness,can givepeopleasenseofcontrolovertheirpain,lessenthe needformedication,andraisetheiroverallqualityoflife. Talkingtoamedicalprofessionalaboutpsychologicalpain managementmethodsmightbehelpfulifyouarehaving pain.
-ShreyasiShelke
Pediatriccancerisaglobalproblemthatchildrenand
theirfamiliesstrugglewith.Almost500,00children willbediagnosedwithcancerthisyearandnearly allofthewillexperiencepainduringtheirfirstyear.Pain managementinchildrenremainsanenormousunmet medicalneedthatisnotcurrentlyservedbycurrent practices.Becauseoftherelativehomogeneityofpainin cancer(proceduralpainandpainfromcanceritself),Nen Evidence-BasedSolutionS.L.U (nen),aclinical-stage companyisdevelopingevidence-baseddigitaltherapeutics tohelpkidsfightingcancer,theirfamiliesandtheirdoctors managepain.
Painmanagementisaddressedthroughplay,byleveraging gamificationofcognitivebehavioraltherapytomodulate painandimproveachild'soverallwell-beingandoutcomes. Throughvalidatedoutcomemeasures,bothfamiliesand physicianscanprovideinsightfulandtailoredpain managementsupporttochildrenwhocurrentlylack alternativemeanstoexpresstheirneeds.
WiththesupportofFrancescaDomenechWuttke (Founder&CEO)andXèniaRiasolCercos(COO),nen isamission-drivenprofit-for-purposecompanyto democratizepainmanagementatscaletoallkidswhoarein pain,wherevertheyare.
Let's dive in to learn about Nen's operations in meeting its objective.
WhenIstartedthinkingaboutmynextsteps,Iwantedtodo somethingwithamoredirectpatientimpact.Iputmy consultinghatbackonanddidascanofthewholeofthe digitalhealthmarkettoidentifygaps.Iwantedtoknow whatthosegapsareandifcantheybefilledwithadigital solutionorservicebutmorespecificallywithadigital therapeutic.
IfeelstronglythatDTxisthefourthwaveofmedicine: smallmolecules,biologics,cellandgenetherapy,andnow digitaltherapeutics.Iwassurprisedbythedearthofactivity inthepediatricdigitalhealthspaceandhadworkedona DTxforpaininadultsandsawhowreadilytheCBT modulescouldbetranslatedtoadigitalplatformand thoughtwhynotapplythattokidsthatwerethegenesisof nen.
Whatarethecorevaluesofthecompany?Howareyou drivingthecompanytoachieveitsmissionandvision statement?
nenisfocusedondevelopingkid-centriccaredesignedfor theirminds-becausekidsmatterandwearecommittedto kids.
nen offers a novel mission-driven approach to address pain management through play leveraging gamifica on approaches and cogni ve behavioral therapy (CBT) to modulate pain and improve their overall well-being and outcomes. We are crea ng an app-based pla orm for smartphones/tablets. The CBT modules will be age- appropriate and designed for children to be engaging and enjoyable for them.
About the Founder
Francesca Wu ke is the CEO and Founder of nen-bringing evidencebased Digital Therapeu cs (DTx)pain solu ons to kids with cancer. Dr. Wu ke brings broad drug development and healthcare exper se in both the US and Europe, with nearly 30 years of clinical, commercial, strategic and transac onal experience. She has worked with diverse organiza ons including start-ups, consul ng, large and specialty pharma as well as academia. Formerly, she was the Chief Digital Officer of Almirall where she created the Almirall Digital Garden to accelerate and incubate digital health startups. Dr. Wu ke worked at Novar s where she was responsible for two Cell and Gene therapy opportuni es that were successfully brought into the organiza on as well as managing the strategy and commercializa on for the exis ng por olio of cell therapy assets.
Dr. Wu ke holds a Ph.D. in Pharmacology from Weill Cornell Graduate School of Medical Sciences and a BA from Cornell University College of Arts and Sciences.
Francesca Domenech Wu ke Founder & CEO Nen Evidence Based Solu ons, S.L.U. (nen)
Xènia Riasol is the Chief Opera ng Officer of nen. She is experienced in launching digital therapeu cs across Europe and in crea ng and deploying customer-centric digital solu ons globally. Xenia is a digital innova on and strategy expert with a focus on commercializa on models and global solu on deployment. She has extensive experience in Pharma, where she was bringing digital innova ve solu ons to pa ents and managing strategic digital marke ng campaigns globally. As Chief Opera ng Officer, Xenia is responsible for leading the product planning and evolu on, marke ng strategies, and for the everyday running of the business, turning industry knowledge into ac onable business channels and revenue streams for the company. She works with investors, partners, advisors and pa ents to manage the strategy and path forward for nen.
Howbigistheaddressablemarket?
Painmanagementinchildrenremainsanenormousunmet medicalneedthatisnotcurrentlyservedbycurrent practices.Todate,nocurrentsolutionsexisttomoderate paindesignedspecificallyforkids.Thecurrentmodalities includingpainassessmentandthentreatmentscalesare incrediblysubjectiveandnotappropriatelymodifiedforuse inchildren,particularlyinsmallchildren.
nenoffersanovelmission-drivenapproachtoaddresspain managementthroughplayleveraginggamification approachesandcognitivebehavioraltherapy(CBT)to modulatepainandimprovetheiroverallwell-beingand outcomes.Wearecreatinganapp-basedplatformfor smartphones/tablets.TheCBTmoduleswillbeageappropriateanddesignedforchildrentobeengagingand enjoyableforthem.
Whoareyourtargetcustomers?
nen'sfirstindicationisforschool-agedchildrenfrom7-12 yearsold,astheyhavemoredeveloped neurodevelopmentalskillswhereCBTisconsidereda clinicallyvalidatedandwell-establishedtherapy.Afterwe haveestablishedasolidandtestedtheregularnensolution (withprovenefficacyandlearnings)nenwillcontinueto developtheplatformtoservepatientsfrom2-6asthisage groupremainsahugeunmetneedasveryfewdigital solutionsforpainmanagementareaddressedspecificallyto themandyettheytoosufferfrompain(bothphysicallyand psychologically).Wewillthenexpandtoadolescents.
Asanexperiencedleader,whatadvicewouldyouliketo givetoaspiringentrepreneursandenthusiastswhowish toventureintothecompetitiveindustrythatyouare serving?
Patienceandresilience.Therewillbealotofno'salong yourpathbutifyoustaytruetoyourmissionandvision youcanachievegreatthings.
Whatarethefuturegoalsofthecompany?Howdoesit envisionscalingupitsoperationsandreachin2023and beyond?
Wehavedesignedourbusinessmodelwithflexsothatwe arenotreliantontheever-changingregulatorylandscape.
Ÿ B2C:Thefirstiterationisapediatriconcologypatient supporttool,designedforGDPR/HIPAAandISO complianceatinceptionandwithparalleldevelopment inUSandEuropeinEnglish(UKandAmerican) Spanish,French,Italian,German,andDutch.Thistool willinitiallybetargetedtoparentssowecanbeta-test theoutcomes.Weexpecttolaunchthisproductinlate 2023andthenafteritisclinicallyvalidated,wewill offerapremiumproduct(identicaltothePDT)with robustmedicalclaimsatahigherpricepoint.
Ÿ B2B:Next,wewillcontinuetoforgeresearch collaborationswithacademicinstitutionstogenerate clinicalevidencewhilegainingchampions.
Ÿ Rx:StandalonePrescriptionDigitalTherapeutic(PDT.) OnceregisteredasSaMD,orunderDiGAorsimilar laws,wewillseekreimbursementasastandalonePDT acrossvariouspayorsystems,modelsandgeographies.
Inseveralhealthcarespecialisms,doctorsand
caregiversareoftenpuzzledaboutthebestwaytohelp theirpatientscopewithpainandanxiety,twodominant concernsoftheirsuffering.
Thisisbecausepatientsduringtreatmentsareusually focusedontheirpain,whichincreasestheirperceptionof pain.Notonlydotheyfeelanxiousaboutit,buttheyalso endupfeelinghelplessandoutofcontroloverthesituation. Inresponsetosuchapaindilemma,distractionhasproven tobeaneffectivecopingtooltohelppatientsreducetheir painandanxiety.Itencouragesthemtofocusonaspecific task(i.e.,apleasurableactivity,puzzles,games,etc.)and attainasenseofcontrol.
Withtheproveneffectivenessofdistractionasatool, RescapeInnovationLimitedprovidesauniquesolutionto easethelivesofpatients.ItsClass-oneinnovativemedical device,DR.VR™,enablesquick,easyandmonitorable deploymentofvirtualrealitytherapytoimprovethe patients'reportedlevelofpainandhasbeeneffective comparedtoopioidanalgesics.
InaninterviewwithInsightsCare,MattWordley,the CEO,talksabouttheroleofvirtualrealityinclinical practice,alongwithRescape'scontributionindeliveringit toimprovetheexperienceofpatients'painandanxiety.
Kindlybriefusaboutthecompanyanditsinception story.
RescapeInnovationwasbornwhenIattendedaTEDtalk byapalliativecareconsultant,ProfessorMarkTaubert, whoexplainedthedifficultiesofcommunicatingwithhis patientcohort.ThereIdevelopedaninterestinimmersive technologythroughotherbusinessinterestsandfeltthatI
wouldbeabletousethetechnologytoaddresssomeofthe issuesthathadbeenraisedintheTEDtalk.Ispoketo ProfessorTaubertimmediatelyafterthetalkandthejourney ofRescapebegan!
Pleasetellusaboutyourselfandyourprofessional journeysofar.
IamoneoftheoriginalcreatorsofTheOrchardMedia EventsGroup.Ihavebeeninstrumentalinbuildingitintoa world-classagency,TVproductioncompanyandLive Musicpromoter AsanearlieradopterandadvocatorofVR technologywithinOrchard,Rescapewasspunouttounlock thehealthcareopportunity,andItookthereignsasCEO.
Whatarethecorevaluesofthecompany?Howareyou drivingthecompanytoachieveitsmissionandvision statement?
VeryearlyonwesawtheimpactthatVirtualReality Therapiescouldhaveonpatients'painandanxiety This wasanecdotalbutveryclearandwestartedtoevidencethis impact.Wecommittedthentohelpingasmanypatientsas possiblehaveaccesstoVRtreatments.Thiscorevalueisan importantprinciplewetrytobenchmarkeverythingwedo against.VRshouldbeavailabletoallandwe'redetermined todeliveragainstthispromise.
Couldyoupleaselistthekeyproductsandofferingsof thecompany?Also,pleaseputlightonanyservicethat isthecompany'sUSP.
DR.VRisaClass1medicaldevicethatisbeingutilizedby hospitals,carehomesandhospicestoalleviateanxietyand reducetheperceptionofpainforpatientsandfamily membersofpatients.AnotherproductisFrontline,which hasbeendesignedtosupportthewell-beingofNHSstaff andhasalsobeenadoptedbyseveraluniversitiestosupport staffandstudents.
Thepriorityforourdevelopmentteamisonensuringthat user-centricdesignisattheheartofallwedoasthatgives ustheabilitytodeploysimplesolutionsatscale,ensuring thatthebenefitsofimmersivetherapeuticsareenjoyedby aswideanaudienceaspossible.
Inyouropinion,whatarethecurrentchallengesinthe painmanagementindustry?Howareyouinfusingyour leadershipskillsandexpertiseovertheyearstocreatea flourishingindustrywithopportunitiesandgrowth?
Weareatthebeginningofafundamentalshiftinmedicine adoptingamoreholisticviewofthepatient.Historically mentalandphysicalhealthhavebeentreatedindependently asiftheywereunconnectedandthisdivideisveryslowly beingbridged.
Painisacomplex,multifacetedbiopsychosocialproblem thatrequiresasolutionthataddressesmultipleelements concurrentlyandchronicpainclinicsarenowstartingto useamultidisciplinaryapproachtotreatmentinvolving psychiatrists,psychologists,anesthetists,physiotherapists, nursesandoccasionallysocialworkers.
Ourjobistobuildtheevidencebasetoprovethat ImmersiveTherapeuticsshouldbeanimportantcomponent
Very early on we saw the impact that Virtual Reality Therapies could have on patients' pain and anxiety. This was anecdotal but very clear and we started to evidence this impact. Based on the Virtual Reality principle, our innovative product, DR.VR, is a Class 1 medical device that is being utilized by hospitals, care homes and hospices to alleviate anxiety and reduce the perception of pain for patients and family members of patients.
Matt Wordley CEO Rescape innovation Limited
intreatingpainbyaddressingmentalandphysicalhealthat thesametimeandbecomeamainstayinthesuiteof treatmentoptionstohelppatients.
Whatarethelatesttechnologicaladvancementsadopted byyourcompanytodeliverthebestpainmanagement servicesintheindustry?Howisitimpactingthe demographicconcerned?
Wecallourselvespragmatictechnologists;therealworldis nevereasyandalwaysmessy WeareproudthatourDR.VR solutionisuser-friendlyforbothpatientsandclinicians.We haveaphraseweusewhendevelopingcontent"Don't createthingstowatchbutspacetoinhabit."Thisisakey remitforsuccessfulVRpaintherapies;thedeeperlevelof immersionwecreate,themoresuccesswecancreate.
Asanexperiencedleader,whatadvicewouldyouliketo givetoaspiringentrepreneursandenthusiastswhowish toventureintothecompetitiveindustrythatyouare serving?
Understandthecompletesystemyouaretryingtowork within.Sadlyit'snotgoodenoughtojustcreateaVirtually Realitythathastherapeuticbenefits.Youhavetodelivera simpleanddeployablesolution.Readup,researchand
embraceuser-centricdesignpracticeandyouwilldevelop muchbettersolutions.Attimesthatmeansembracingthe elephantintheroomandtacklingthehardthingshead-on. Therearesomanyexampleswherewehavedonethisfrom alackofNHSwifitoinfectioncontrolprotocolsormaking sureourcontentreducesmotionsickness.
Whatarethefuturegoalsofthecompany?Howdoesit envisionscalingupitsoperationsandreachin2022and beyond?
TheopportunitiesfortheuseofVRinhealthcarearein theirinfancy Wehaveseveralexcitingresearchprojects thatwillbeconcludingin2023andwe'reexcitedaboutthe opportunitiesthiswillopen.Referencingourcorevalues, wewanttogiveaccesstoasmanypeopleaspossibleandin '23wewillbelaunchingapainsolutionthatcanbe accessedfromhome.Thisinpart,isdrivenbyagrowing numberofpatientsthathaveaskediftheycanusethe solutionathome.
Giveusafewtestimonialsfromyourclientsor customersandawardsorrecognitionthataccurately highlightyourcompany'spositioninthemarket.
"VRinterventiondemonstratedasignificantreductionin patientandparentalanxietybothpre-operativelyandinthe fractureclinic."
"Theimprovementinpatients'reportedpainafterVR, particularlyforthosepatientswithhigherpainscores(3.41 pointsoutof10),wasremarkableandiscomparablewith opioidanalgesics."
Dr.CeriLynch,publishedinICUManagement.
“91%[ofpatients]reportedloweranxietylevelsafterusing theheadset."
Potter,T.,Curran,Jr,2021UsingDR.VR®inaBurns Unit
"Ihavebeenanurseforover25years,workingmainlyin cancerandpalliativecare,andthiswasprobablyoneofthe mostamazing,movingandbeautifulexperiencesIhave witnessed."
Gillian,LeadNurse,MarieCurieHospice,Newcastle
"Themindfulnessareasteachingmehowtocalmand breathewereamazingformyworryandanxiety."
PID105,FRONTLINERELIEF:Abriefevaluation
"Ithinkit'sreallygoodfortakingyououtofastressful environmentandcalmingyoudown.Ilikethattherewere lotsofdifferentoptionsforwhattodobecausepeoplehave verydifferentpreferences."
UniversityHospitalBristol&WestonEvaluation Documentation
Painisanexperiencethataffectspeopleofallages,
racesandgenders.Itisauniversalfeeling.Several things,likeinjuries,illnessesandlong-term conditions,canbringiton.Becauseitcanincreasea patient'scapacityfordailyactivitiesandimprovetheir qualityoflife,painmanagementisanessentialpartof healthcare.
Thetwomostcommontypesofpainareacuteandchronic. Acutepainistypicallybroughtonbyasuddenoccurrence suchassurgery,bonefractures,infections,cutsand lacerations,falls,andburns.Adoctorusuallytreatsacute painimmediatelyfollowingthetriggeringevent.Thepain typicallysubsidesastheinjuryorconditionheals,generally disappearingwithinsixmonths.
Let's have a look at techniques to manage pain!
Prescriptionsare,muchofthetime,theprimarylineof treatmentfortorment.Theyfallintooneoftwocategories: opioidandnon-opioiddrugs.
Over-the-counterpainrelieverslikeacetaminophenand ibuprofenandprescriptionmedicationslikenon-steroidal anti-inflammatorydrugs(NSAIDs)areexamplesofnonopioidmedications.Drugslikemorphine,oxycodoneand fentanylaresomeexamplesofopioids.
Anothereffectivemethodformanagingpainisphysical therapy.Itinvolvesstretching,exercises,andotherphysical methodstoincreasemobilityanddecreasepain.Patients withmusculoskeletalconditionslikebackpain,arthritisand fibromyalgiamaybenefitmostfromphysicaltherapy.
Actualadvisorscanworkwithpatientstofoster individualizedtreatmentdesignsthatfocusonthe underlyingdriveroftheiraggravation.Theseplansmay includemanualtherapy,therapeuticexercise,andotherheat orcoldtherapytreatments.
Theseinterventions,likemindfulnessmeditationand cognitive-behavioraltherapy(CBT),canalsobehelpfulin painmanagement.Positivethoughtpatternsthatcan exacerbatepainareidentifiedandchangedinCBT.Care reflectionincludeszeroinginonthecurrentsecondand toleratingactualsensationswithoutjudgment.
Patientsmaybenefitfromthesemethodsindeveloping copingmechanismsthatlessentheimpactofpainontheir dailylives.Theycanalsoimprovemoodandlowerstress levels,whichcanhelpbreakthecycleofchronicpain.
Findingthemosteffectivepainreliefmethodsforone's conditioncantakesometimeduetothecomplexityof chronicpain.Yoga,drugtreatments,andhotandcold therapyarejustafewoptionsavailable.
Aninjuryoramedicalconditioncanleadtochronicpain.If painpersistsformorethanthreemonths,orifitcontinues beyondthestandardhealingperiodfortheunderlying conditionorinjury,itisconsideredchronic.Itcanimpact everythingfromaperson'sworkandsociallifetotheir sleepandmentalhealth.
TheCentresforDiseaseControlandPrevention(CDC) estimatedthatapproximately20%ofadultsintheUnited Stateshadchronicpain,with8%experiencinghigh-impact chronicpain.
AccordingtotheTrustedSourceGlobalBurdenofDisease Studyfrom2017,chronicpainandrelateddiseasesarethe leadingcausesofdisabilityworldwide.Ithasarelationship withvariousphysicalandpsychologicalwell-being conditions,includingwretchedness,restissues,social segregationandabuseofprescription.
Hotandcoldtreatmentisatypicalandsafemethodto lessentorment.Intensitycanassistwithlooseningupthe musclesandenlargingtheveins.Itcanalsohelpwounds healafteranaccident.
Coldtherapyreducespain-causinginflammationandblood flow Theskinisfrequentlytreatedwithanicepack wrappedinatowel.
Apractitionerperformsacupuncturebyinsertingfine needlesintotheskinatspecificpointsonthebody
TheNationalCentreforComplementaryandIntegrative, HealthTrustedSourcesaysthatthereisevidencetosuggest thatthismethodcouldassistindividualsinmanaging certainpainconditions.Thisincludestemporaryrelieffrom osteoarthritisandlowerback,neckandkneepain. However,thereislittleevidencetosuggestthatitislonglastinglyeffective.
Acupuncturehasbeensuggestedtoalleviatepain,reduce inflammation,promoterelaxationandlessenmuscle spasms.Whenperformedbytrainedpractitionerswith sterileneedles,acupunctureisgenerallysafe.
Yogausesspecificposesthattargetspecificbodypartsto relax,strengthenandkeepthebodyflexible. Areportin2010,intoyoga'sconsequencesforongoing torment,foundthatitdidn'tdiminishmembers'aggravation. Yet,itassistedthemwithadapting,andtheyweremorein chargeofwhattheiraggravationmeantfortheirday-to-day existence.
Ontheotherhand,yogahasbeenshowntoreducepainin otherstudies.Itisasafeandeasywaytomanagepain.You cantryitathome,watchingvideosonline,orinaclasswith ateacher.
In conclusion,
Managingpainandchronicpaincanbedoneinseveral ways,manyofwhichareaccessibleandstraightforwardto use.Mostpainmanagementmethodsaimtolessenor enhanceaperson'scapacitytocopewithchronicpain.
Aprofessionaltherapistshouldbeusedforpain managementtechniqueslikeacupuncture,physicaltherapy andyogatoensureanyonecansafelypracticethem.
-ShreyasiShelkeTheoldwives’taleoftakingouthotwaterbottlesto
reducebodypainhassometruthinit.Andscience istakingitseriously.Heatprovidescomforttothe body,andcanreducepainatthereceptorlevelwiththe righttemperatureandapplication.SoovuLabs,Inc.has usedthismechanismatitscoreforthediscoveryofnew drug-freepainrelieftreatments.Whileit'sdifficulttouse electricheatingpadsandhottubsonthegoandsteadyhigh temperaturescandamagetheskin,thecompanyhassolved thesechallengeswithitsSoovu™PainReliefSystem.
Soovu™isawearablepainreliefdevicewithpatented HeatWave™technologythatpulseswavesofheatat optimaltemperaturestotheareathathurts,foreffective, targetedpainrelief.Thisdevicedeliversfastandeffective relief,leavinguserspain-freeandcomforted.Followingare thekeybenefitsthatsettheSoovu™deviceapartfrom otherheat-deliverymechanisms.
Ÿ Reliefstartsinaslittleasfiveminutes.
Ÿ Lastingreliefupto3.5hours.
Ÿ 61%painreductionaftereightweeks.
Ÿ Wirelessandcanbeusedon-the-go.
InaninterviewwithInsightsCare,AllanStephan,the CEOandCo-founder,talksin-depthaboutthecompany's innovationintreatingpaindrug-free.
Following are the excerpts from the interview
Kindlybriefusaboutthecompanyanditsinception story.
SoovuLabsistransformingthetreatmentofpainby providingsafe,effectivealternativestopillsandinvasive procedures.Thecompanywasfoundedbytwoboardcertifiedpainspecialistswhogrewincreasinglyfrustrated watchingmanypatients’livescompromisedbyopioid
dependenceandotherpatientsdemoralizedafternumerous proceduresfailedtomeaningfullyreducetheirpain.After securingfundingfromtheNationalInstitutesofHealth, theyteamedupwithAllanStephan,aseasonedengineer andproductdesignexecutive,todeveloptheSoovu™ wearablethermalneuromodulationsystemforpainrelief.
Pleasetellusaboutyourselfandyourprofessional journeysofar.
Iworkonsolvingcomplexproblemsandhaveaspecial appreciationforthedifferentskillsandeffortrequiredto unlockpuzzles.Anengineerbydegree,Ifoundedmyfirst company,Stratos,amulti-disciplineproductdevelopment firm,in1987.Stratos'clienteleincludedventurecapital backcompaniesandmajororganizationslikeApple, Microsoft,Intel,Google,Amazon,BostonScientific, Medtronic,andAbbott.
Iincubatedseveralemergingcompaniesinwearable computing,medicaldevicesandlifescienceswithin Stratos.VoxWareacquiredInroad(wearablecomputer)in 2000.SonyacquiredMicronics(microfluidicdiagnostics) in2010.MilliporeacquiredAmnis(imagingflow cytometry)in2010.RocheacquiredStratosGenomics (DNAsequencing)in2020.
In2016,IsteppeddownfromStratostoleadmyremaining incubationtoaddresstheworld'spainepidemic,Soovu Labs.
Whatarethecorevaluesofthecompany?Howareyou drivingthecompanytoachieveitsmissionandvision statement?
SoovuLabs'objectiveistohelpeveryonebethebestthey canbe.Isurroundmyselfwithincrediblepeople,cleartheir paths,andletthemrolloutsolutions.
Allan Stephan
Co-founder and CEO
Unlike typical pain relief solutions, Soovu delivers relief within 5 minutes of the first heat therapy, is drug-free, and can be used discreetly and safely at work, home, rest or play. Quick and e cient pain relief can improve mobility, mood, sleep and productivity as well as reduce the need for pain medication and pain therapies.
Couldyoupleaselistthekeyproductsandofferingsof thecompany?Also,pleaseputlightonanyservicethat isthecompany’sUSP.
SoovuLabs’flagshipproductistheSoovu™PainRelief System,anFDA-registeredclassIImedicaldeviceforthe temporaryreliefofchronicandmusculoskeletalpainand menstrualdiscomfort.Soovuisavailablewithout prescriptionandiscurrentlymarketedasadrug-free workforcepainmanagementsolution.Unliketypicalpain reliefsolutions,Soovudeliversreliefwithin5minutesof thefirstheattherapy,isdrug-free,andcanbeused discreetlyandsafelyatwork,home,restorplay.Quickand efficientpainreliefcanimprovemobility,mood,sleepand productivityaswellasreducetheneedforpainmedication andpaintherapies.
Inyouropinion,whatarethecurrentchallengesinthe painmanagementindustry?Howareyouinfusingyour leadershipskillsandexpertiseovertheyearstocreatea flourishingindustrywithopportunitiesandgrowth?
Thegreatestchallengeofpainistreatingitwithoutcreating evenmoredangerousoutcomes.Whetherfromaddictionto
injuryfromNSAIDs,treatingpainisarisk.Mycareerhas beenlookingatproblemsfromnon-traditionalanglestosee whatothersmissed.Weareadvancingknowledgebeyond existingtherapiesbylookingatpain'spivotalroleinthe immunesystem.Weseevariationsofourworkinpain managementrollingoutforyearstocome.
Whatarethelatesttechnologicaladvancementsadopted byyourcompanytodeliverthebestpainmanagement servicesintheindustry?Howisitimpactingthe demographicconcerned?
TheSoovu™PainReliefSystemtargetstheTRPV1 receptor,whichwasthefocusofNobelPrize-winning researchin2021ontemperatureandpressure-sensitive receptors.Soovu'spatentedHeatWave™thermal neuromodulationtechnologydesensitizestheTRPV1 receptortoblockthepainresponseforseveralhours.Soovu deliversreliefwithinminutes,onparorfasterthanmost medications,anddoessowithouttheriskofsevereside effects.Itsportableformfactorandabilitytouseonthego makeSoovuanidealdrug-freepainreliefsolutionfor individualswhoneedreliefastheycarryonwiththeirlives.
Asanexperiencedleader,whatadvicewouldyouliketo givetoaspiringentrepreneursandenthusiastswhowish toventureintothecompetitiveindustrythatyouare serving?
Ifyouaren'tanaturalsalesperson,getyourselfanequal partnerbecausesuccessiscreatingsomethingpeopleare willingtobuy,andittakeslongerthanyou'llimagine.
Whatarethefuturegoalsofthecompany?Howdoesit envisionscalingupitsoperationsandreachin2023and beyond?
EstablishingSoovuasthesafestandmostenjoyablemethod ofpainreductionwillalwaysbeourgoal.Thisyear,weare kickingoffpilottrialswithmajorcorporationstoaddress theenormousnegativeimpactemployeesinpainhaveon anorganization'sprofitabilitywhiledemonstratingSoovu's positiveimpactonemployees’lives.Soovuwilleventually addressclinicalpainapplicationsandconsumersolutionsin yearstocome.
Giveusafewtestimonialsfromyourclientsor customers,andawardsorrecognitionthataccurately highlightyourcompany’spositioninthemarket.
”
“ThefirsttimeIusedmySoovuIhadmusclespasmsinmy back,typicallyIneedachiropractorormassagetherapyto workthoseout,butwhenIputSoovuonithelpedcalmthe musclesdown.MySoovuhasbecomeaveryusefultoolfor whenIoverdoitonewayoranothertohelpmegetbackto activelife.”
-ErikL,SoovuUser Entrepreneur,suffersfromarthritis,avidathlete.
"Soovuhelpsmepinpointtheareathatishurting.Forme, it'sinstantsatisfaction.IlikethatIcanstickitonwherever Iwantandgoonwithmyday,soIamnotstuckonthe couch.Ibringthekitwithmeanduseitatwork.Iletsome ofmyco-workersborrowmypodsandtheyswearbyit,my wifelovesit,it’sagreatproduct.”
-ScottS,SoovuUser Building
Engineer,suffersfromchronicbackpainfrom injury.
“Forme,reliefwasprettymuchimmediateandlonglasting”
“IrecentlyhadababyandI’vehadalotoflowerbackpain sincethen.SinceI’vebeenbreastfeeding,Itrytominimize medicationsforpainandjusttakeanoccasionalTylenol,so tohaveSoovuasanadjuncttherapyforpainhasbeen incrediblyhelpful.I’veusedheatinthepasttohelpwith pain,butSoovuisdifferent.Youcanfeeltheheatright away,inaverytargetedplacewhereyoufeelpain.Relief wasprettymuchimmediateformeandlong-lasting."
-SheenaH,SoovuUser Anesthesiologist/PainPhysician,suffersfrombackpain.
